Showing results (801-810 of 848) with videos related to

Sort By:
Pageof 85
The Journal of Infectious Diseases|May 16, 2024
Extended-Spectrum β-Lactamase Shigella sonnei Cluster Among Men Who Have Sex With Men in Chicago, Illinois, July-October 2022Emily A G Faherty, Kendall Kling, Hannah J Barbian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 29, 2020
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter StudySeung Up Kim, Yeon Seok Seo, Han Ah Lee, et al.
Scientific Reports|August 29, 2025
Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis BJae Seung Lee, Sung Won Lee, Hae Lim Lee, et al.
Journal of Hepatology|April 9, 2019
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South KoreaSeung Up Kim, Yeon Seok Seo, Han Ah Lee, et al.
The Korean Journal of Internal Medicine|January 25, 2023
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myelomaHee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, et al.
Cell Transplantation|June 8, 2010
Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosisJa Kyung Kim, Young Nyun Park, Jin Seok Kim, et al.
Blood|June 12, 2026
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01)Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, et al.
Medicine|June 15, 2017
Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort studyJung Gil Park, Won Young Tak, Soo Young Park, et al.
Investigational New Drugs|September 11, 2018
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, et al.
Journal of Liver Cancer|July 7, 2025
Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteriaHyun Yang, Soon Sun Kim, Seong Hee Kang, et al.
Pageof 85